AOD 9604 5 mg

Dragon Pharma

  • Active Substance: Anti-Obesity Drug-9604 (AOD 9604)
  • Concentration: 5 mg per vial
  • Pack Size: Lyophilized vial for injection-based research
  • Manufacturer: Dragon Pharma
  • Brand Name: AOD9604
  • Molecular Formula: C78H123N23O23S
  • Molecular Weight: 1815.1 g/mol
  • Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
  • Synonyms: hGH 176–191 fragment, Fat Loss Peptide, Lipolytic GH Fragment
$75.00
$75.00
In Stock
Manufacturer Dragon Pharma
Brand AOD9604
Substance Anti-Obesity Drug-9604
Concentration 5 mg
Pack Size vial
Shipping

AOD 9604 5 mg by Dragon Pharma is a synthetic peptide fragment modeled after human growth hormone (HGH), specifically the lipolytic region responsible for fat breakdown. While it does not induce anabolic effects like full-length HGH, it retains the ability to activate beta-adrenergic lipolytic pathways. This makes it an ideal candidate for research in obesity, metabolic regulation, and adipose tissue remodeling.

Mechanism of Action

AOD 9604 is derived from amino acids 176–191 of the growth hormone molecule. This truncated sequence is believed to enhance fat degradation by stimulating lipolysis and inhibiting lipogenesis, without elevating blood sugar or triggering insulin resistance. Studies suggest it activates enzymes such as hormone-sensitive lipase (HSL), facilitating the release of stored fatty acids into circulation.

Unlike growth hormone, AOD 9604 does not promote IGF-1 release, making it attractive for metabolic-focused research without the muscular hypertrophy or endocrine feedback complications associated with GH analogs. It has also been explored for joint repair, cartilage regeneration, and general metabolic recovery in murine and primate studies.

Key Features & Benefits

  • Targeted Fat Metabolism: Studied for its ability to enhance lipolysis without influencing muscle growth pathways.
  • Low IGF-1 Interaction: Does not stimulate insulin-like growth factor, supporting clean metabolic targeting in experiments.
  • Supports Obesity Research: Investigated for weight loss models and adipose-related disorders in preclinical settings.
  • Joint & Cartilage Benefits: Secondary studies suggest regenerative support for cartilage and soft tissues.
  • Precision Formulation: Manufactured by Dragon Pharma for high-purity injectable peptide research.

Frequently Asked Questions

1. Does AOD 9604 really work?
In controlled studies, AOD 9604 has shown promising fat reduction effects through enhanced lipolysis without affecting lean muscle mass or IGF-1 levels.
2. What are the side effects of AOD 9604?
AOD 9604 has shown a favorable safety profile in research, with minimal systemic side effects due to its selective action. However, full toxicological data is still under review.
3. How much weight do you lose on AOD?
Weight reduction depends on study duration, species, and dose. In murine models, significant fat mass decrease was observed without changes in food intake or lean mass.